Evidence map›Paper›PMID 42553490›Full record

ReviewResearch (Washington, D.C.)2026

Engineering Organoid Platforms for Pathogenesis Research.

Xiaolu Han, Jun Zhang, Jiahui Bai, Weiming Tian, Jie Zhou, Lihua Ding, Xiang Gao

Abstract readReview
In one paragraph

Review in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaolu HanNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, 100071 Beijing, China.
Jun ZhangNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, 100071 Beijing, China.
Jiahui BaiNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, 100071 Beijing, China.
Weiming TianSchool of Life Science and Technology, Harbin Institute of Technology, 150080 Harbin, China.
Jie ZhouDepartment of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Lihua DingNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, 100071 Beijing, China.ORCID https://orcid.org/0009-0004-0818-1392
Xiang GaoNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, 100071 Beijing, China.ORCID https://orcid.org/0009-0009-4372-4627

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging and re-emerging infectious diseases ranging from the 1918 H1N1 influenza pandemic to the recent SARS-CoV-2 and monkeypox virus outbreaks continue to pose profound threats to global public health. These crises underscore the critical need for high-fidelity and human-relevant infection models. Organoid technology has emerged as a cornerstone platform for pathogen research by faithfully recapitulating the 3-dimensional architecture and physiological microenvironment of native human tissues in vitro. This review systematically examines the development and structural refinement of organoid-based infection models with an emphasis on evidence-based strategies for stem cell source selection, extracellular matrix optimization, and dynamic culture system engineering. Such advancements enable the robust generation of multi-organ models including respiratory, intestinal, and neural organoids tailored for investigating viral tropism, spatiotemporal infection kinetics, and host immune responses. Furthermore, we evaluate the translational utility of organoids in high-throughput antiviral drug screening and preclinical vaccine assessment. To further enhance physiological relevance and functional fidelity, organoid platforms are being increasingly combined with advanced engineering strategies, including coculture approaches, CRISPR-Cas9-mediated genetic perturbation, engineered microphysiological systems (such as organ-on-a-chip), and 3D bioprinting. These integrated technologies improve biomimicry while expanding experimental controllability and scalability. In addition, we critically examine the major bottlenecks limiting clinical translation and discuss emerging frontiers driven by artificial intelligence and synthetic biology. Through iterative technological refinement and cross-disciplinary convergence, organoids have evolved beyond reductionist in vitro surrogates into physiologically informed and mechanism-driven platforms that advance our understanding of host-pathogen interactions while enhancing global preparedness against emerging pathogens.

Identifiers

PMID42553490
PMCPMC13433924

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.